Vaxart announces that its COVID-19 investigational new drug (IND) application for an oral vaccine has been filed with the FDA.

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced that its COVID-19 Investigational New Drug (IND) application has been filed with the FDA. The company expects its upcoming Phase I study to generate data that will further differentiate its oral vaccine from injectable vaccines by substantiating the importance of activating both systemic and mucosal immunity in protecting against COVID-19. The company believes that this mechanistic benefit combined with the significant advantages of oral administration to the patient while eliminating the need for cold chain distribution, could make its COVID-19 vaccine an ideal candidate for successful mass vaccination campaigns globally.